merck p53 peptide vaccine patent Merck - merck-peptides P53 VACCINES FOR THE TREATMENT OF CANCERS Merck's p53 Peptide Vaccine Patent: A Deep Dive into Cancer Therapy Innovation

men-s-peptide-moisturizer The pursuit of effective cancer treatments has long been a central focus for pharmaceutical giants like Merck. A significant area of investigation involves the p53 protein, a critical tumor suppressor, and its potential role in therapeutic vaccines2020年10月25日—peptidethat binds with high affinity to endogenousp53inhibitors MDM2 and. MDMX. Treatment with ALRN-6924 increases intracellularp53levels .... This exploration delves into the Merck p53 peptide vaccine patent landscape, examining how Merck and other entities have sought to leverage peptides derived from or targeting p53 to combat various cancers.

The p53 protein, often referred to as the "guardian of the genome," plays a vital role in preventing uncontrolled cell proliferation.Merck seeks patents on cancer treatments, medications for ... When p53 is mutated or inactivated, it can significantly contribute to cancer development.Mutant p53 peptide pulsed dendritic cell vaccine(University ... Consequently, researchers have explored strategies to restore or harness the power of p53 function. One such strategy involves developing p53 peptide vaccines. These vaccines aim to stimulate the immune system to recognize and attack cancer cells that express or are affected by p53 abnormalities2008年12月4日—Figure 1:Patentcount versus Assignees: the top three assignees for adenovirusvaccinerelatedpatentsareMerck,. University of ....

Merck's involvement in this field is evident through various patent filingsAffymetrix all~ges infringement of USpatentnumber 5,445,934 entitled ''Array of oligonucleotides on a solid substrate." The timing of the lawsuit is puzzling.. For instance, U.S. Patent NoPatents Assigned to Merck Sharp & Dohme Corp.. 8,663,646 B2, titled "P53 peptide vaccine," describes an invention related to a peptide derived from p53 that could serve as a vaccine against cancer. This aligns with the broader concept of peptide vaccines where specific fragments of disease-associated proteins are used to elicit an immune response. Another relevant patent, U.S. Patent No. 9,527,896 B2, titled "Stabilized p53 peptides and uses thereof," further indicates a focus on developing and stabilizing the p53 peptides for therapeutic applications, presumably within vaccine formulations.

Beyond direct p53 vaccination, research has also focused on targeting proteins that regulate p53, such as HDM2 (Human Double Minute 2) and MDMX. By inhibiting these regulators, the activity of p53 can be enhanced.Affymetrix all~ges infringement of USpatentnumber 5,445,934 entitled ''Array of oligonucleotides on a solid substrate." The timing of the lawsuit is puzzling. This approach is reflected in patents like "P53 activator peptidomimetic macrocycles" and "Targeted MDM2 Degradation." These peptide mimetics and degradation strategies aim to indirectly bolster p53's tumor-suppressing capabilities, offering another avenue for cancer treatment. The patent landscape also shows a keen interest in inhibiting E3 ubiquitin ligase MDM2/MDMX, which are known to inhibit p53's tumor suppressor function, thus allowing for accelerated mutation-driven cancer progression.US9527896B2 - Stabilized p53 peptides and uses thereof

The development of p53-based vaccines is not exclusive to Merck.Targeted MDM2 Degradation Reveals a New Vulnerability for ... The patent literature reveals a broader scientific effort2020年7月21日—A number of companies have announced candidates for a COVID-19vaccine, including Moderna Therapeutics ($MRNA), AstraZeneca ($AZN), Johnson & Johnson ($JNJ) .... For example, WO 2006/124700, titled "P53 Vaccines for the Treatment of Cancers," highlights the global interest in this therapeutic area. Additionally, mutant p53 has become a focus for some research, as seen in the "Mutant p53 peptide pulsed dendritic cell vaccine" concept, suggesting a strategy to target specific, altered forms of the p53 protein. Research into targeting a neoantigen derived from a common TP53 mutation further underscores this direction.

The versatility of peptide technology extends to various vaccine platforms.The following list identifiesMerck'srights in USpatentsassociated with the relevant product. This list may be a subset ofMerck'srights in USpatents... The development of mRNA vaccines, as mentioned in U.SPeptide vaccine formulations and use thereof for inducing an .... 2019/0008938 A1 ("Concatemeric peptide epitope rnas"), demonstrates how peptide sequences can be incorporated into novel delivery systems. Furthermore, peptide vaccines targeting tumor-associated antigens, including P53, are being explored in clinical trials, such as the randomized phase III trial referencing peptides restricted to HLA-A2 phenotype targeting tumor-associated antigens like P53.(12) United States Patent - Googleapis.com

While the p53 genetic vaccine initially developed by the National Cancer Institute has seen its research status as discontinued, the underlying principles of stimulating an immune response against p53-related mechanisms continue to drive innovation.作者：EHC Hsiue·2021·被引用次数：370—Hsiue et al. discovered a way to target a cancer-associated mutant form of thep53protein using the body's own immune system. The Merck p53 peptide vaccine patent portfolio, alongside numerous other patents and research initiatives, underscores the enduring scientific and commercial interest in unlocking the therapeutic potential of p53 and peptide vaccine strategies for improved cancer treatment. The ongoing exploration of peptide inhibitors, peptide mimetics, and various vaccine modalities signifies a dynamic field with the ultimate goal of developing more effective therapies against a wide spectrum of cancers.